A review of tasquinimod in the treatment of advanced prostate cancer

References

• Siegel R Naishadham D Jemal A Cancer statistics, 2012 CA Cancer J Clin 2012 62 1 10 29 22237781
   PubMed Web of Science ®Google Scholar
• Chamberlain J Melia J Moss S Brown J The diagnosis, management, treatment and costs of prostate cancer in England and Wales Health Technol Assess 1997 1 3 i vi 1 53 9414542
   PubMedGoogle Scholar
• Tannock IF de Wit R Berry WR Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 351 15 1502 1512 15470213
   PubMed Web of Science ®Google Scholar
• de Bono JS Oudard S Ozguroglu M TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 2010 376 9747 1147 1154 20888992
   PubMed Web of Science ®Google Scholar
• Reid AH Attard G Danila DC Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 2010 28 9 1489 1495 20159823
   PubMed Web of Science ®Google Scholar
• Ferlay J Parkin DM Steliarova-Foucher E Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 2010 46 4 765 781 20116997
   PubMed Web of Science ®Google Scholar
• Jemal A Siegel R Xu J Ward E Cancer statistics, 2010 CA Cancer J Clin 2010 60 5 277 300 20610543
   PubMed Web of Science ®Google Scholar
• Feldman BJ Feldman D The development of androgen-independent prostate cancer Nat Rev Cancer 2001 1 1 34 45 11900250
   PubMed Web of Science ®Google Scholar
• Pienta KJ McGregor N Axelrod R Axelrod DE Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments Transl Oncol 2008 1 4 158 164 19043526
   PubMed Web of Science ®Google Scholar
• Jain RK Au P Tam J Duda DG Fukumura D Engineering vascularized tissue Nat Biotechnol 2005 23 7 821 823 16003365
   PubMed Web of Science ®Google Scholar
• Hanahan D Folkman J Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364 8756718
   PubMed Web of Science ®Google Scholar
• Bergers G Benjamin LE Tumorigenesis and the angiogenic switch Nat Rev Cancer 2003 3 6 401 410 12778130
   PubMed Web of Science ®Google Scholar
• Weidner N Carroll PR Flax J Blumenfeld W Folkman J Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 1993 143 2 401 409 7688183
   PubMed Web of Science ®Google Scholar
• Hartley-Asp B Vukanovic J Joseph IB Strandgården K Polacek J Isaacs JT Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer J Urol 1997 158 3 Pt 1 902 907 9258116
   PubMed Web of Science ®Google Scholar
• Joseph IB Isaacs JT Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers Cancer Res 1997 57 6 1054 1057 9067270
   PubMed Web of Science ®Google Scholar
• Vukanovic J Hartley-Asp B Isaacs JT Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers Prostate 1995 26 5 235 246 7538663
   PubMed Web of Science ®Google Scholar
• Vukanovic J Isaacs JT Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers Cancer Res 1995 55 7 1499 1504 7533663
   PubMed Web of Science ®Google Scholar
• Vukanovic J Passaniti A Hirata T Traystman RJ Hartley-Asp B Isaacs JT Antiangiogenic effects of the quinoline-3-carboxamide linomide Cancer Res 1993 53 8 1833 1837 7682157
   PubMed Web of Science ®Google Scholar
• Wolinsky JS Narayana PA Noseworthy JH Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators Neurology 2000 54 9 1734 1741 10802777
   PubMed Web of Science ®Google Scholar
• Noseworthy JH Wolinsky JS Lublin FD Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators Neurology 2000 54 9 1726 1733 10802775
   PubMed Web of Science ®Google Scholar
• Jonsson S Andersson G Fex T Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship J Med Chem 2004 47 8 2075 2088 15056005
   PubMed Web of Science ®Google Scholar
• Isaacs JT Pili R Qian DZ Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer Prostate 2006 66 16 1768 1778 16955399
   PubMed Web of Science ®Google Scholar
• Dalrymple SL Becker RE Zhou H DeWeese TL Isaacs JT Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts Prostate 2012 72 6 638 648 21837778
   PubMed Web of Science ®Google Scholar
• Isaacs JT Antony L Dalrymple S Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment Cancer ResEpub 11 13 2012
   Google Scholar
• Olsson A Björk A Vallon-Christersson J Isaacs JT Leanderson T Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors Mol Cancer 2010 9 107 20470445
   PubMed Web of Science ®Google Scholar
• Jennbacken K Welén K Olsson A Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3- carboxamide tasquinimod (ABR-215050) Prostate 2012 72 8 913 924 22287276
   PubMed Web of Science ®Google Scholar
• Kallberg E Vogl T Liberg D S100A9 interaction with TLR4 promotes tumor growth PLoS One 2012 7 3 e34207 22470535
   PubMed Web of Science ®Google Scholar
• Björk P Björk A Vogl T Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides PLoS Biol 2009 7 4 e97 19402754
   PubMed Web of Science ®Google Scholar
• Vogl T Tenbrock K Ludwig S Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock Nat Med 2007 13 9 1042 1049 17767165
   PubMed Web of Science ®Google Scholar
• Corzo CA Condamine T Lu L HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment J Exp Med 2010 207 11 2439 2453 20876310
   PubMed Web of Science ®Google Scholar
• Squadrito ML De Palma M Macrophage regulation of tumor angiogenesis: implications for cancer therapy Mol Aspects Med 2011 32 2 123 145 21565215
   PubMed Web of Science ®Google Scholar
• Bunt SK Clements VK Hanson EM Sinha P Ostrand-Rosenberg S Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4 J Leukoc Biol 2009 85 6 996 1004 19261929
   PubMed Web of Science ®Google Scholar
• Bottomley MJ Lo Surdo P Di Giovine P Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain J Biol Chem 2008 283 39 26694 26704 18614528
   PubMed Web of Science ®Google Scholar
• Lahm A Paolini C Pallaoro M Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases Proc Natl Acad Sci USA 2007 104 44 17335 17340 17956988
   PubMed Web of Science ®Google Scholar
• Joseph IB Nelson JB Denmeade SR Isaacs JT Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue Clin Cancer Res 1997 3 12 Pt 1 2507 2511 9815654
   PubMed Web of Science ®Google Scholar
• Colombel M Filleur S Fournier P Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate Cancer Res 2005 65 1 300 308 15665307
   PubMed Web of Science ®Google Scholar
• Dalrymple SL Becker RE Isaacs JT The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts Prostate 2007 67 7 790 797 17373719
   PubMed Web of Science ®Google Scholar
• Garcia-Barros M Paris F Cordon-Cardo C Tumor response to radiotherapy regulated by endothelial cell apoptosis Science 2003 300 5622 1155 1159 12750523
   PubMed Web of Science ®Google Scholar
• Vergis R Corbishley CM Norman AR Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study Lancet Oncol 2008 9 4 342 351 18343725
   PubMed Web of Science ®Google Scholar
• Sonveaux P Brouet A Havaux X Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy Cancer Res 2003 63 5 1012 1019 12615716
   PubMed Web of Science ®Google Scholar
• Stuben G Thews O Pöttgen C Stuschke M Sack H Tumour oxygenation during fractionated radiotherapy – comparison with size-matched controls Acta Oncol 1999 38 2 209 213 10227443
   PubMed Web of Science ®Google Scholar
• Crokart N Jordan BF Baudelet C Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions Int J Radiat Oncol Biol Phys 2005 63 3 901 910 16199320
   PubMed Web of Science ®Google Scholar
• Hou H Lariviere JP Demidenko E Gladstone D Swartz H Khan N Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy Radiother Oncol 2009 91 1 126 131 19013657
   PubMed Web of Science ®Google Scholar
• Bratt O Häggman M Ahlgren G Nordle O Bjöork A Damber JE Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer Br J Cancer 2009 101 8 1233 1240 19755981
   PubMed Web of Science ®Google Scholar
• Pili R Häggman M Stadler WM Phase II randomized, doubleblind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer J Clin Oncol 2011 29 30 4022 4028 21931019
   PubMed Web of Science ®Google Scholar
• Scher HI Halabi S Tannock I Prostate Cancer Clinical Trials Working Group Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 2008 26 7 1148 1159 18309951
   PubMed Web of Science ®Google Scholar
• Dupont A Gomez JL Cusan L Koutsilieris M Labrie F Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy J Urol 1993 150 3 908 913 7688437
   PubMed Web of Science ®Google Scholar
• Scher HI Beer TM Higano CS Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Lancet 2010 375 9724 1437 1446 20398925
   PubMed Web of Science ®Google Scholar
• Yamaoka M Hara T Hitaka T Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys J Steroid Biochem Mol Biol 2012 129 3–5 115 128 22249003
   PubMed Web of Science ®Google Scholar
• Chen M Adeniji AO Twenter BM Winkler JD Christianson DW Penning TM Crystal structures of AKR1C3 containing an N-(aryl) amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer Bioorg Med Chem Lett 2012 22 10 3492 3497 22507964
   PubMed Web of Science ®Google Scholar
• Mitsiades N Sung CC Schultz N Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors Cancer Res 2012 72 23 6142 6152 22971343
   PubMed Web of Science ®Google Scholar
• Yu EY Wilding G Posadas E Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 2009 15 23 7421 7428 19920114
   PubMed Web of Science ®Google Scholar
• Kantoff PW Schuetz TJ Blumenstein BA Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 2010 28 7 1099 1105 20100959
   PubMed Web of Science ®Google Scholar
• Sheikh NA Petrylak D Kantoff PW Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer Cancer Immunol Immunother 2013 62 1 137 147 22865266
   PubMed Web of Science ®Google Scholar
• Parker CC Pascoe S Chodacki A A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (ra 223) in patients with bone metastases and castration-resistant prostate cancer Eur Urol 2013 63 2 189 197 23000088
   PubMed Web of Science ®Google Scholar
• Bergers G Hanahan D Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 2008 8 8 592 603 18650835
   PubMed Web of Science ®Google Scholar
• Casanovas O Hicklin DJ Bergers G Hanahan D Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 2005 8 4 299 309 16226705
   PubMed Web of Science ®Google Scholar
• Pollard JW Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 2004 4 1 71 78 14708027
   PubMed Web of Science ®Google Scholar
• Du R Lu KV Petritsch C HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion Cancer Cell 2008 13 3 206 220 18328425
   PubMed Web of Science ®Google Scholar
• Jain RK Booth MF What brings pericytes to tumor vessels? J Clin Invest 2003 112 8 1134 1136 14561696
   PubMed Web of Science ®Google Scholar
• Mancuso MR Davis R Norberg SM Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 2006 116 10 2610 2621 17016557
   PubMed Web of Science ®Google Scholar
• Bikfalvi A Moenner M Javerzat S North S Hagedorn M Inhibition of angiogenesis and the angiogenesis/invasion shift Biochem Soc Trans 2011 39 6 1560 1564 22103487
   PubMed Web of Science ®Google Scholar
• Rubenstein JL Kim J Ozawa T Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2000 2 4 306 314 11005565
   PubMed Web of Science ®Google Scholar
• Ogita S Tejwani S Heilbrun L Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer ISRN oncology 2012 2012 242850 22745916
   PubMedGoogle Scholar